- 2-4 weeks treatment; 6-12 months monitoring
- 1-2 weeks post-procedure; metabolic benefits develop over 3-6 months
- 66%
China versus the U.S.
- China clinical rate
- $6,000 – $18,000
- $12,000
- United States
- $20,000 – $50,000
- $35,000
- You save
- ~66%
- $23,000 per procedure
Prices are approximate ranges. Actual cost depends on hospital, surgeon, materials, and case complexity.
What the procedure involves.
Investigational stem cell therapy for type 1 and type 2 diabetes aiming to restore pancreatic beta cell function and improve insulin sensitivity. Chinese research hospitals conduct clinical trials using mesenchymal stem cells, induced pluripotent stem cells, and encapsulated islet-like cells. Programs combine cell therapy with metabolic management and lifestyle optimization.
Step by step.
Metabolic Assessment
C-peptide levels, HbA1c, islet autoantibody testing, and comprehensive metabolic panel
Cell Therapy Planning
Protocol selection based on diabetes type, residual beta cell function, and treatment goals
Stem Cell Administration
Intravenous MSC infusion or interventional delivery to pancreatic vasculature
Metabolic Monitoring
Serial C-peptide, insulin requirements, HbA1c tracking, and dose adjustments over 12 months
- Potential to reduce insulin requirements or achieve insulin independence
- Chinese hospitals have extensive diabetes stem cell trial experience
- Combined with comprehensive metabolic optimization
- May slow or halt autoimmune destruction in type 1 diabetes
- Experimental treatment — not standard of care
- Variable response rates across patients
- Potential for transient fever and infusion reactions
- Long-term durability of benefit uncertain
Ask the AI for hospitals that handle stem cell therapy for diabetes.
Prices shown are approximate ranges for reference only. Actual costs vary by hospital, complexity, and individual patient needs. Always consult with healthcare professionals for medical decisions.